Trial Profile
A retrospective study evaluating efficacy and safety of Macitentan transitioned from Bosentan in patients with Pulmonary Arterial Hypertension
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Nov 2018
Price :
$35
*
At a glance
- Drugs Macitentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Therapeutic Use
- 01 Nov 2018 New trial record
- 19 Sep 2018 Results presented at the 28th Annual Congress of the European Respiratory Society